Curaleaf Holdings (CURLF) Non-Current Deferred Tax Liability (2019 - 2025)
Curaleaf Holdings (CURLF) recorded quarterly Non-Current Deferred Tax Liability of $235.1 million in Q4 2025, down 11.79% quarter-over-quarter from $266.5 million in Q4 2024, and down 11.79% on a YoY basis from $266.5 million in Q4 2024.
Curaleaf Holdings (CURLF) Non-Current Deferred Tax Liability (2019 - 2025) Analysis & Trends
Curaleaf Holdings' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $235.1 million for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability fell 11.79% year-over-year to $235.1 million; the TTM figure through Dec 2025 stood at $235.1 million (down 11.79% YoY), while the FY2025 annual figure was $235.1 million, down 11.79% from the prior year.
- Non-Current Deferred Tax Liability was $235.1 million for Q4 2025 at Curaleaf Holdings, down from $266.5 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $342.6 billion in Q1 2022 to a low of $222.6 million in Q1 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $24.7 billion across 5 years, with a median of $302.3 million in 2021.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability soared 153837.26% in 2022, then decreased 11.79% in 2025.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $257.8 million in 2021, then advanced by 28.91% to $332.3 million in 2022, then fell by 9.38% to $301.1 million in 2023, then declined by 11.5% to $266.5 million in 2024, then declined by 11.79% to $235.1 million in 2025.
- The last three Non-Current Deferred Tax Liability figures came in at $235.1 million (Q4 2025), $266.5 million (Q4 2024), and $276.2 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Curaleaf Holdings | - | - | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 235.08 Mn |
| Dec 31, 2025 | 235.08 Mn |
| Dec 31, 2024 | 266.49 Mn |
| Dec 31, 2024 | 266.49 Mn |
| Sep 30, 2024 | 276.22 Mn |
| Sep 30, 2024 | 276.22 Mn |
| Jun 30, 2024 | 285.59 Mn |
| Jun 30, 2024 | 285.59 Mn |
| Dec 31, 2023 | 301.13 Mn |
| Dec 31, 2023 | 301.13 Mn |
| Sep 30, 2023 | 311.04 Mn |
| Sep 30, 2023 | 311.04 Mn |
| Jun 30, 2023 | 318.21 Mn |
| Jun 30, 2023 | 318.21 Mn |
| Sep 30, 2022 | 332.31 Mn |
| Sep 30, 2022 | 332.31 Mn |
| Jun 30, 2022 | 334.81 Mn |
| Jun 30, 2022 | 334.81 Mn |
| Mar 31, 2022 | 342.61 Bn |
| Mar 31, 2022 | 342.61 Bn |